[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642292":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":78,"collaborators":25,"id":80,"slug":25,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":25,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":25,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Aspeya, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"ASY202, Then Placebo","EXPERIMENTAL","ASY202 is a pre-metered drug-device combination product containing DHE dry powder formulation for oral inhalation, delivered via a dry powder inhaler (DPI) device. In Treatment Period 1, participants will receive ASY202, followed by a washout period and subsequent administration of placebo in Treatment Period 2. The placebo consists of an inactive inhalation powder delivered via a matching DPI device.",[13,14],"Combination Product: ASY202","Combination Product: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Placebo, Then ASY202","In Treatment Period 1, participants will receive placebo inhalation powder delivered via a dry powder inhaler (DPI) device, followed by a washout period and subsequent administration of ASY202 in Treatment Period 2.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"COMBINATION_PRODUCT","ASY202","ASY202 is a pre-metered drug-device combination product containing a dry-powder formulation of dihydroergotamine (DHE) intended for oral inhalation, delivered via a dry powder inhaler (DPI).",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Placebo inhalation powder delivered via a dry powder inhaler (DPI) device.",[9,16],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Eken","CONTACT","+41 76 358 88 30","clinicaltrials@aspeya.com",[37,53,66],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Sunwise Clinical Research, Llc","RECRUITING","Walnut Creek","California","94596","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-122.06496,37.90631,{"lat":49,"lon":48},[52],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"M3 Wake Research - Las Vegas Rainbow","NOT_YET_RECRUITING","Las Vegas","Nevada","89118",{"type":46,"coordinates":60},[61,62],-115.13722,36.17497,{"lat":62,"lon":61},[65],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"facility":67,"status":55,"city":68,"state":69,"zip":70,"country":43,"countryCode":44,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Highland Research","Salt Lake City","Utah","84124",{"type":46,"coordinates":72},[73,74],-111.89105,40.76078,{"lat":74,"lon":73},[77],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"type":79,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100642292",false,"NCT07646613","Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients","A Randomized, Double-blind, Placebo-controlled, Crossover, Multi-center Clinical Trial for the Evaluation of Efficacy, Safety, and Tolerability of ASY202 for the Acute Treatment of Migraine in Adult Patients","Inclusion Criteria:\n\n* Able to understand study procedures and provide written informed consent\n* Male or female, 18-65 years of age at Screening\n* BMI between 18.5-35 kg\u002Fm² at Screening\n* Documented history of migraine (with or without aura) for ≥1 year, consistent with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* Female participants must be either:\n\n  * of non-childbearing potential, or\n  * of childbearing potential using protocol required contraception\n\nExclusion Criteria:\n\n* Diagnosis of headache conditions other than migraine\n* History or current diagnosis of coronary artery disease (CAD)\n* History or current diagnosis of coronary artery vasospasm (including Printz-metal's angina), clinically significant arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation) or peripheral vascular disease, ischemic disease (e.g., Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia)\n* History of percutaneous coronary intervention, cardiac surgery, sepsis or vascular surgery\n* History or current diagnosis of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, or subarachnoid hemorrhage\n* Known history or current diagnosis of psychological and\u002For psychiatric condition that, in the opinion of the Investigator, might interfere with study participation and assessments or participant safety. These conditions may include depression, psychosis, schizophrenia, bipolar disorder, dementia, alcoholism, drug abuse, etc.\n* Known allergic reactions, hypersensitivity, or contraindications to DHE, other ergot-derived products, or any other excipient in the formulation\n* Use of strong or moderate CYP3A4 inhibitors within 14 days (or 5 half-lives) or CYP3A4 inducers within 28 days (or 5 half-lives) prior to Randomization\n* Any clinically significant symptoms or conditions at screening, other than migraine, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions, or history of such conditions that in the opinion of the Investigator, might interfere with study assessments or participant safety","ALL","18 Years","65 Years",{"count":90,"type":91},108,"ESTIMATED","INTERVENTIONAL",[94],"PHASE2","This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a placebo (inactive treatment) at different times during the study. Neither participants nor study staff will know which treatment is given at the time. The medication is taken using a handheld dry powder inhaler to treat migraine attacks when they occur.\n\nFollowing screening, eligible participants will be enrolled and randomized to one of two treatments sequences i.e. one treatment sequence will receive ASY202 in treatment period 1 followed by placebo in treatment period 2 and other treatment sequence will receive placebo in treatment period 1 followed by ASY202 in treatment period 2.\n\nThe study lasts about 16 weeks and includes a screening period, two treatment periods (with a minimum of 7 days washout period between the treatment periods), and a safety follow-up visit.",[97],"Migraine",[97,99,100],"DHE","Dihydroergotamine Mesylate","2026-06-15",{"date":103,"type":104},"2026-06-16","ACTUAL",{"date":106,"type":104},"2026-05-19",{"date":108,"type":91},"2026-12",{"name":5,"class":6},3]